一种GTF2H4高表达的内皮细胞系
By constructing a cell line with high GTF2H4 expression in human microvascular endothelial cells and using lentiviral vector technology to achieve GTF2H4 overexpression, we have addressed the shortcomings in endothelial-mesenchymal transition studies, promoted endothelial-mesenchymal transdifferentiation and migration of endothelial cells under hypoxic conditions, and inhibited tube formation ability, providing a foundation for in-depth research.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- ZHONGSHAN HOSPITAL FUDAN UNIV
- Filing Date
- 2022-04-24
- Publication Date
- 2026-07-17
AI Technical Summary
Current research on endothelial-mesenchymal transition is still immature, lacking new targets to reverse endothelial-mesenchymal transformation and improve cardiovascular disease, and the role of GTF2H4 in this process has not been reported.
A double-stranded DNA fragment carrying a 3xflag tag was constructed, and high expression of GTF2H4 was achieved in human microvascular endothelial cells HMEC-1 using lentiviral vector overexpression technology. Cells were then prepared and infected using a recombinant lentiviral vector to promote endothelial-mesenchymal transdifferentiation.
High expression of GTF2H4 significantly promotes endothelial-mesenchymal transdifferentiation of endothelial cells under hypoxic conditions, enhances cell migration ability, and inhibits tube formation ability, providing convenient conditions for exploring the molecular mechanism of endothelial-mesenchymal transformation.
Smart Images
Figure CN115572730B_ABST